ReviewDigestive diseases and sciences2026
Diet in Inflammatory Bowel Diseases: Efficacy, Tolerability, and Microbiome Effects Toward Personalized Management.
Review in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInflammatory bowel disease (IBD) is increasingly recognized as a condition in which diet is not only a trigger for symptoms but also a potential tool for disease modulation. Mounting evidence links dietary patterns and specific nutrients to intestinal inflammation, microbiome composition, and mucosal repair, opening new avenues for personalized therapy. DIET
interventionsExclusive and partial enteral nutrition remain among the most effective nonpharmacologic strategies in Crohn's disease, while emerging data support the Mediterranean diet, specific carbohydrate diet, and low Fermentable Oligo-, Di-, Mono-saccharides And Polyols (FODMAP) approaches for symptom relief and quality-of-life improvement. GAPS AND FUTURE DIRECTIONS: Nevertheless, evidence is often heterogeneous, with variability in dietary protocols, endpoints, and patient populations, making firm recommendations challenging. Adherence and long-term sustainability remain major barriers, underscoring the need for realistic, patient-centered approaches. By integrating current findings with clinical practice, diet can evolve from supportive care to a central component of multidisciplinary IBD management-if guided by robust evidence and tailored to individual needs. As research continues to refine the role of specific foods, nutrients, and patterns, dietary therapy holds promise not only to complement pharmacologic treatments but also to address the broader nutritional and metabolic needs of patients living with IBD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.